Is Panitumumab available in the country?

It is understood that the original drug Panitumumab (Panitumumab) has not yet been launched in China, so it has not been covered by medical insurance. The price of the Hong Kong original version of Panitumumab 100mg/5mL sold in Hong Kong, China, may be around 9,000 yuan (the price may fluctuate due to exchange rates). Panitumumab is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) who have wild-type RAS, as defined in KRAS and NRAS, as determined by FDA-approved trials for this use. As monotherapy after disease progression in patients who have previously received chemotherapy containing fluoropyrimidine, oxaliplatin, and irinotecan; it can also be combined with FOLFOX as first-line treatment.